Receives one 483 observation for Jeedimetla facility
Granules India announced that the USFDA completed inspection of its Gagillapur facility without any 483 observation while it received 1 observation for Jeedimetla facility. The inspection at the two facilities was conducted from 19 March to 23 March 2018.Gagillapur facility manufactures finished dosage and pharmaceutical formulation intermediates whereas Jeedimetla facility manufactures active pharmaceutical ingredients and pharmaceuticals formulations intermediates.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
